Most Read Articles
Stephen Padilla, 29 Sep 2020
The coronavirus disease (COVID-19) pandemic appears to have quickened the acceptance of prescription digital therapeutics (PDT), or software that helps treat human disease, by clinicians and patients, particularly those suffering from mental health conditions, according to experts from one of the sessions at the 2020 Virtual Forum of the Asia Pacific Medical Technology Association (APACMed 2020).

Mental health problems spell trouble for diabetics

3 days ago
5 ways to diminish the anxiety of your perioperative patient

Mental health comorbidities are common among patients with type 2 diabetes mellitus (T2DM) and may lead to worse outcomes, a recent study has found.

This suggests that the management of T2DM should also include screening for mental health problems, so that interventions may be delivered in a timely manner.

The researchers conducted a retrospective observational analysis of 63,365 T2DM patients (mean age, 69.9±12.1 years; 54.0 percent male). Most (n=51,335) were without mental health comorbidities, which included depression, anxiety, schizophrenia, or substance use disorder.

In the remaining 12,030 patients, depression (13.6 percent) and anxiety (3.17 percent) were the most common comorbidities. The presence of such comorbidities increased the risk of all T2DM outcomes assessed in the study.

For example, the risk of 4-year all-cause mortality was significantly elevated in T2DM patients with at least one mental health comorbidity (adjusted odds ratio [OR], 1.24, 95 percent confidence interval [CI], 1.16–1.31; p<0.001), though different comorbidities led to different magnitudes of effect. Substance use disorder most strongly affected mortality risk.

Moreover, having at least one mental health comorbidity likewise increased the risk of all-cause hospitalization (adjusted OR, 1.16, 95 percent CI, 1.10–1.23; p<0.001), T2D hospitalization (adjusted OR, 1.51, 95 percent CI, 1.18–1.93; p=0.001), and emergency room visits (adjusted OR, 1.26, 95 percent CI, 1.21–1.32; p<0.001) among T2D patients. For all above outcomes, substance use disorder was the strongest risk factor.

“These findings underline the need for developing global management strategies to facilitate the prevention, early detection, diagnosis and monitoring of mental health comorbidities in T2D patients,” the researchers said.

“The high prevalence of multimorbidity found in T2D patients highlights the importance of providing continuity of care and person-centred approaches to improve the management and outcome of this chronic disease,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 29 Sep 2020
The coronavirus disease (COVID-19) pandemic appears to have quickened the acceptance of prescription digital therapeutics (PDT), or software that helps treat human disease, by clinicians and patients, particularly those suffering from mental health conditions, according to experts from one of the sessions at the 2020 Virtual Forum of the Asia Pacific Medical Technology Association (APACMed 2020).